- Home
- NPKI vs PHAR Comparison
NPKI vs PHAR Comparison
Compare NPKI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- PHAR
- Stock Information
- Founded
- NPKI 1932
- PHAR 1988
- Country
- NPKI United States
- PHAR Netherlands
- Employees
- NPKI N/A
- PHAR N/A
- Industry
- NPKI Metal Fabrications
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- PHAR Health Care
- Exchange
- NPKI Nasdaq
- PHAR Nasdaq
- Market Cap
- NPKI 881.5M
- PHAR 951.7M
- IPO Year
- NPKI N/A
- PHAR N/A
- Fundamental
- Price
- NPKI $10.76
- PHAR $14.60
- Analyst Decision
- NPKI Strong Buy
- PHAR Strong Buy
- Analyst Count
- NPKI 3
- PHAR 3
- Target Price
- NPKI $12.17
- PHAR $30.00
- AVG Volume (30 Days)
- NPKI 664.3K
- PHAR 12.7K
- Earning Date
- NPKI 11-06-2025
- PHAR 10-23-2025
- Dividend Yield
- NPKI N/A
- PHAR N/A
- EPS Growth
- NPKI N/A
- PHAR N/A
- EPS
- NPKI N/A
- PHAR N/A
- Revenue
- NPKI $234,741,000.00
- PHAR $339,836,000.00
- Revenue This Year
- NPKI $19.94
- PHAR $16.63
- Revenue Next Year
- NPKI $9.36
- PHAR $6.77
- P/E Ratio
- NPKI N/A
- PHAR N/A
- Revenue Growth
- NPKI 6.96
- PHAR 22.44
- 52 Week Low
- NPKI $4.76
- PHAR $7.31
- 52 Week High
- NPKI $10.99
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- NPKI 65.88
- PHAR 56.71
- Support Level
- NPKI $10.35
- PHAR $13.63
- Resistance Level
- NPKI $10.75
- PHAR $15.27
- Average True Range (ATR)
- NPKI 0.24
- PHAR 0.96
- MACD
- NPKI -0.02
- PHAR -0.13
- Stochastic Oscillator
- NPKI 73.30
- PHAR 51.83
About NPKI NPK International Inc. Common Stock
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.